Cellular and humoral immunity to SARS‐CoV‐2 infection in multiple sclerosis patients on ocrelizumab and other disease‐modifying therapies: a multi‐ethnic …
…, TE Bacon, L Zhovtis Ryerson, P Raut… - Annals of …, 2022 - Wiley Online Library
Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity to …
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity to …
Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate‐to‐severe asthma
M Chen, K Shepard, M Yang, P Raut… - Clinical & …, 2021 - Wiley Online Library
Background Current biologic therapies target allergic, eosinophilic or type 2 inflammation
phenotypic asthma. However, frequency and degree of overlap among these subtypes is …
phenotypic asthma. However, frequency and degree of overlap among these subtypes is …
Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies
…, I Stanzin, MI Samanovic, P Raut… - Annals of Clinical …, 2022 - Wiley Online Library
Objective To compare “hybrid immunity” (prior COVID‐19 infection plus vaccination) and
post‐vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying …
post‐vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying …
[HTML][HTML] Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis
…, A Boster, J Katz, G Pardo, J Pei, P Raut… - Multiple Sclerosis and …, 2020 - Elsevier
Background Ocrelizumab is an approved MS treatment administered as two 300-mg
intravenous infusions 2 weeks apart (Dose 1), each lasting approximately 2.5 hours, followed by …
intravenous infusions 2 weeks apart (Dose 1), each lasting approximately 2.5 hours, followed by …
[HTML][HTML] No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities
M Chen, E Choo, B Yoo, P Raut, T Haselkorn… - Annals of Allergy …, 2021 - Elsevier
Background Comorbidities are common in asthma and may complicate treatment response.
Objective To examine response to omalizumab in patients with moderate-to-severe allergic …
Objective To examine response to omalizumab in patients with moderate-to-severe allergic …
[HTML][HTML] Similar response to omalizumab in children with allergic asthma from different racial backgrounds
…, LA Millette, CTJ Holweg, J Ko, P Raut… - The Journal of …, 2023 - jaci-inpractice.org
Racial and ethnic minority populations in the United States, especially Black children, endure
an increased burden of asthma due to factors such as environmental exposure, access to …
an increased burden of asthma due to factors such as environmental exposure, access to …
Impact Of Food Allergy On Work Productivity And Healthcare Resource Use In Patients With Allergic Asthma Treated With Omalizumab
…, S Gupta, MH Zacharia, B Cameron, P Raut… - Journal of Allergy and …, 2024 - jacionline.org
Methods In this post-hoc analysis of EXCELS, a prospective, observational study (NCT00252135),
patients aged≥ 12 years with moderate-to-severe allergic asthma were grouped by …
patients aged≥ 12 years with moderate-to-severe allergic asthma were grouped by …
Impact of Patient Baseline Characteristics On Work Productivity and Activity Impairment Following Omalizumab Treatment In Patients With Allergic Asthma
R Katial, B Creasy, P Raut, H Pazwash… - Journal of Allergy and …, 2024 - jacionline.org
Methods The prospective, observational EXCELS study (NCT00252135) followed patients≥
12years with moderate-to-severe persistent asthma treated with/without omalizumab for≤ …
12years with moderate-to-severe persistent asthma treated with/without omalizumab for≤ …
[PDF][PDF] Omalizumab Is Efficacious in Children With Allergic Asthma From Different Racial Backgrounds
…, P Huang, LA Millette, J Ko, P Raut… - ANNALS OF …, 2021 - medically.gene.com
Background• In the United States, underserved racial and ethnic populations, 1 especially
Black children, 2 experience an increased burden of asthma.
Black children, 2 experience an increased burden of asthma.
Hybrid and vaccine-induced immunity against SARS-CoV-2 in MS patients on different disease-modifying therapies (preprint)
…, AV Calderon, F Dibba, S Idga, M Samanovic, P Raut… - 2022 - pesquisa.bvsalud.org
Objective: To compare'hybrid immunity'(prior COVID-19 infection plus vaccination) and post-vaccination
immunity to SARS CoV-2 in MS patients on different disease-modifying …
immunity to SARS CoV-2 in MS patients on different disease-modifying …